GLP-1s

A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect on an individual’s risk of developing obesity-related cancers.  The study, published Dec. 9 in Annals…

Wegovy and Zepbound, two popular weight loss GLP-1 medications, would remain cost-effective at a higher price, according to an Oct. 29 revised report from the Institute for Clinical and Economic Review.  The estimated annual net price for Eli Lilly’s Zepbound…

In October, GLP-1 manufacturers inked partnerships with big-box retailers to increase access as several studies indicate a low adherence rate for the expensive medications.  Three updates on the GLP-1 drug class:  1. Prescriptions go unfilled Despite expanded approvals for conditions…

As of Oct. 17, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications. The approved indications for brand-name GLP-1s: Bydureon (exenatide) Type 2 diabetes in patients ages 10…

GLP-1 medications, originally approved for diabetes, are rapidly expanding into new therapeutic territory — from cardiovascular to anti-inflammatory effects.  Norma Keller, MD, chief of cardiology at NYC Health + Hospitals/Bellevue, recently told Becker’s prevention programs should embrace these therapies.  “We…

A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective option to treat obesity.  The findings mark a shift…

Eli Lilly’s experimental oral GLP-1 medication, orforglipron, led to an average weight loss of 12.4%, or 27.3 pounds, in a phase 3 trial involving more than 3,000 adults.  Based on the results, the drugmaker said Aug. 7 it plans to…

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers.  Starting July 1, WeightWatchers will collaborate with Humana’s CenterWell Pharmacy to fulfill and deliver prescriptions…

U.K. regulators have launched a study into a possible genetic link between use of GLP-1s, such as Ozempic, Mounjaro and Wegovy, and acute pancreatitis.  Yellow Card Biobank, a joint initiative of Genomics England and the government, is calling for patients…

After three years, only about 1 in 12 individuals taking GLP-1s to treat obesity remained on the therapy, according to a Prime Therapeutics study published on June 25. Prime is owned by 19 Blue Cross and Blue Shield plans and…